ResearcherID - CLICK HERE

TITLE:

A RESEARCH STUDY TO EXAMINE THE RANGE AND ASPECTS OF HEPATOCELLULAR CARCINOMA (HCC) AMONG PATIENTS AT TERTIARY HEALTHCARE FACILITY

AUTHORS:

Dr. Abdul Rehman Sarwar, Qurat ul Ain, Dr Ayesha Saddiqa Tarar

ABSTRACT:

Background: All around the globe, the third most contributing factor to death from cancer is hepatocellular carcinoma. Objective: To examine activated aspects among patients of hepatocellular carcinoma (HCC) at a tertiary care centre in the previous two years was the purpose of this research. Material and Methods: We carried out this research at Mayo Hospital, Lahore from January 2017 to August 2018. The patients selected for this study were having HCC identified by histopathology or tumour marker. These patients were examined. Level of alpha-fetoprotein, the presence of cirrhosis, distribution of liver lesions, positivity for hepatitis serology and size of tumour were observed and demographic aspects were noticed. Results: Histopathology and tumour marker proved HCC was observed in 192 patients. The number of males and females were 149 (77.6%) and 43 (22.4%) respectively. 27 (14%) cases were found positive for hepatitis B surface antigen. 138 (72%) patients were positive for HCV. Multicentric distribution was observed in 117 (61%) patients. 134 (70%) patients were noted with cirrhosis and increased level of alpha-fetoprotein was observed in 154 (84%). 16 (8%) patients were found with dual hepatitis (HBV + HCV). The people without any reason were 11 (6%). Conclusion: the results concluded that in most patients, hepatitis C virus infection is associated with hepatocellular carcinoma. The males were more vulnerable to this disorder and it was observed in the fifth and sixth decade of life. Cirrhosis, multicentric and advanced disorder at presentation were observed in the majority of the patients. Keywords: Multicentric, Advanced, Hepatocellular, Hepatitis, HCV, HBV, Carcinoma and Cirrhotic.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.